Connecting healthcare data to digital campaigns
Solving the attribution challenge
Launching a pharmaceutical marketing campaign takes months of planning, creative development, and media strategy—followed by rigorous research and refinement. When the campaign finally goes live, marketers need more than hope; they need confidence. Confidence that they’re reaching the right high-value audience across a fragmented landscape, that targeting and measurement are accurate, and proving that results reflect real-world impact. This confidence starts with one critical factor: the ability to link web activity and user behaviour data sources – both upfront when creating audiences and on the backend during measurement.
The challenge: Linking real-world health data to digital campaigns
Healthcare marketers face a persistent challenge: connecting real-world health data to real-world patients in a HIPAA-compliant way. Many data providers claim to offer high-quality audiences, but what’s the value if those audiences cannot be linked to digital identifiers for campaign measurement? Without accurate linkage to digital identifiers, impressions cannot be tied to meaningful healthcare actions, and marketers are left guessing.
Agencies invest heavily in tagging campaigns, but without secure connectivity between media exposure and patient actions – such as prescription fills or treatment starts - ROI remains unclear. Fragmented data ecosystems and strict privacy regulations make this even harder. Marketers need a solution that bridges these gaps seamlessly—ensuring privacy while enabling accurate attribution and actionable insights.
Why identity durability matters in a fragmented landscape
As the advertising ecosystem continues to evolve, signal loss, platform restrictions, and channel fragmentation are reshaping how healthcare marketers maintain addressability. Durable identity solutions – built on consistent, privacy-safe de-identification – help preserve the connection between audience planning, activation, and measurement even as identifiers fluctuate or disappear.
For healthcare use cases, this is particularly critical: without stable identity linkage, cross-channel audiences lose fidelity, match rates drop, and outcome measurement becomes unreliable. Durable identity is now a foundational requirement for delivering scale responsibly in an increasingly complex environment.
From privacy to performance: Tokenisation’s role in high match rates
In healthcare marketing, HIPAA-compliant data de-identification isn’t just a regulatory requirement—it’s the cornerstone of trust. Tokenisation technology has become a critical enabler of secure data connectivity, allowing marketers to link offline healthcare data with online identifiers without compromising privacy.
High match rates are essential for accurate audience targeting and reliable campaign measurement. When evaluating tokenisation providers, marketers should ask:
- What is the average match rate?
- How is consistency maintained across multiple data partners?
- Are insights delivered quickly enough to support optimisation?
- Is the solution widely adopted and proven?
Consistency, timing, and broad interoperability ensure that data can be connected responsibly while supporting meaningful measurement at scale.
A high-value view of cross-channel activation
Today’s audiences engage across many channels – video, mobile, display, and increasingly privacy-centric environments. Effective healthcare marketing requires the ability to activate de-identified audiences where patients spend time, without losing fidelity or scale in the process.
When tokenisation and identity framework are aligned, marketers can extend audience reach across channels more effectively and measure exposure in a consistent way. While channels differ in signals and identifiers, unified and privacy-safe audience resolution helps ensure campaigns perform as expected while maintaining compliance.
Scalable identity partnership built for interoperability
Symphony Health, an ICON plc company and LiveRamp – an industry leader in data connectivity and identity resolution - bring confidence to healthcare marketers by leveraging advanced tokenisation technology and identity resolution that enables high match rates across Symphony Health’s extensive healthcare data assets. All Symphony Health data is securely de-identified to meet HIPAA standards through Synoma® tokenisation, with LiveRamp implementing the same tokenisation framework to ensure consistency throughout the marketing process and removing any guesswork involved. By resolving data to LiveRamp’s RampID, we can provide advertisers with a secure, consistent identifier that maximises audience fidelity across channels and devices.
This means no barriers to connecting healthcare claims data to patients for audience targeting and media measurement. Marketers can finally link campaign exposure to real-world outcomes with confidence.
The results speak for themselves: with LiveRamp, we are achieving match rates of ~70%, a level that confidently speaks to the campaign’s success. For marketers, this translates into:
- Greater reach to the intended target audience.
- Higher confidence in campaign measurement.
- Improved ability to connect exposure data to meaningful healthcare actions.
Ultimately, this partnership and level of connectivity delivers unparalleled Audience Quality and Measurement, empowering pharmaceutical brands and agencies to make smarter, data-driven decisions.
In an era where precision and compliance are non-negotiable, Synoma® technology—backed by Symphony’s depth of healthcare data and LiveRamp’s identify resolution expertise—sets a new standard for healthcare marketing measurement. It is not just about running campaigns; it’s about running them with confidence.
For more about the partnership between Symphony Health’s data and LiveRamp’s identity resolution capabilities, connect with us today.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
- mHealth wearables
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
- Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Accelerating clinical development through DHTs
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Accelerating clinical development through DHTs
-
Regulatory Intelligence
-
Accelerating access
-
Meeting requirements for Joint Clinical Assessments
-
Navigating the regulatory landscape in the US and Japan:
-
Preparing for ICH GCP E6(R3) implementation
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
Accelerating access
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Demystifying the Systematic Literature Reviews
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
From bottlenecks to breakthroughs
-
Linguistic validation of Clinical Outcomes Assessments
-
More than monitoring
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel